We are live on ! Find out more
SIP

Stoneridge Investment Partners Portfolio holdings

AUM $152M
1-Year Est. Return 20.58%
This Fund
S&P 500
This Quarter Est. Return
+2.12%
1 Year Est. Return
+20.58%
3 Year Est. Return
+44.17%
5 Year Est. Return
+32.14%
10 Year Est. Return
+92.72%
AUM
$265M
AUM Growth
+$1.61M
Cap. Flow
-$4.39M
Cap. Flow %
-1.66%
Top 10 Hldgs %
37.8%
Holding
155
New
33
Increased
20
Reduced
44
Closed
28

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$4.52M
2
CVS icon
CVS Health
CVS
+$4.51M
3
LHX icon
L3Harris
LHX
+$4.09M
4
CRM icon
Salesforce
CRM
+$3.6M
5
DLTR icon
Dollar Tree
DLTR
+$3.6M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$6.62M
2
V icon
Visa
V
+$5.01M
3
HUM icon
Humana
HUM
+$4.83M
4
DLR icon
Digital Realty Trust
DLR
+$4.27M
5
ROK icon
Rockwell Automation
ROK
+$4.18M

Sector Composition

Rank Sector Weight
1 Technology 36%
2 Healthcare 10.46%
3 Industrials 9.79%
4 Financials 9.61%
5 Communication Services 9.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SKWD icon
151
Skyward Specialty Insurance
SKWD
$2.51B
-6,158
Closed -$230K
SNA icon
152
Snap-on
SNA
$21.3B
-3,264
Closed -$967K
V icon
153
Visa
V
$675B
-17,949
Closed -$5.01M
XEL icon
154
Xcel Energy
XEL
$48B
-12,638
Closed -$679K
INFN
155
DELISTED
Infinera Corporation Common Stock
INFN
-21,033
Closed -$127K

Similar funds

Stoneridge Investment Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Stoneridge Investment Partners held 155 positions worth $265M, up 0.61% from $263M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Stoneridge Investment Partners's Q2 2024 filing shows 33 new, 20 increased, 44 reduced and 28 closed positions. Its largest new stake was CVS Health: 72,169 shares worth $4.26M. The largest sale was Pfizer, an estimated $6.62M.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 32% a quarter earlier, followed by Healthcare and Industrials.

  • Stoneridge Investment Partners's largest Q2 2024 buy was CVS Health: 72,169 shares worth $4.26M.
  • Stoneridge Investment Partners added most to Bristol-Myers Squibb in Q2 2024, an estimated $4.52M increase.
  • Stoneridge Investment Partners's biggest Q2 2024 reduction was Alphabet (Google) Class A, cutting an estimated $2.39M.
  • Stoneridge Investment Partners fully exited Pfizer in Q2 2024, selling an estimated $6.62M.
  • Stoneridge Investment Partners's ten largest holdings make up 38% of its $265M portfolio in Q2 2024.
  • Stoneridge Investment Partners opened 33 new positions and closed 28 in Q2 2024.
  • Stoneridge Investment Partners's portfolio value rose 0.61% quarter-over-quarter to $265M.

Based on Stoneridge Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.